First filed March 2020, Updated January 2021; Recruiting
CATEGORIES: General SLE
The purpose of this Phase 3 study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
This study is being offered at 34 LuCIN sites – institutions that are members of the Lupus Clinical Investigators Network managed by Lupus Therapeutics, an affiliate of the Lupus Research Alliance.
To Learn More Contact
Call UCB Cares +1844599 ext 2273 or UCBCares&ucb.com.
ClinicalTrials.gov identifier (NCT number):NCT04294667